Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome, Inc. (NASDAQ: IMNM), a dedicated biotechnology company specializing in creating advanced targeted therapies for oncology, has recently appointed Roee Shahar to the position of Executive Vice President for Commercial operations. With over twenty years of experience, Mr. Shahar has an illustrious track record in the life sciences sector, significantly contributing to the successful launch and commercialization of oncology and hematology products.
Expertise in Oncology and Hematology
Mr. Shahar brings valuable insights from his previous roles at prominent companies such as Seagen, Pfizer, and Eli Lilly & Company. His journey includes the launch of notable treatments in these fields, which have significantly impacted patient care. Under his leadership, the hematology portfolio at Pfizer expanded remarkably, especially following the acquisition of Seagen, where he had previously excelled as Vice President and Franchise Lead.
Strengthening Immunome's Commitment
Clay Siegall, PhD, the President and CEO of Immunome, expressed confidence in the appointment, stating that Roee Shahar will play a crucial role in propelling the company's endeavors in oncology. The expertise Mr. Shahar brings will enhance the advancement of their targeted oncology agents. One key focus is AL102, a gamma secretase inhibitor undergoing a Phase 3 clinical trial intended for treating desmoid tumors, which is critical in developing potentially life-saving therapies.
Passion for Innovative Cancer Solutions
Emphasizing his dedication to combating challenging health conditions, Mr. Shahar shared, "I share the team’s passion to address the debilitating pain, deformity, and life-threatening organ damage caused by desmoid tumors." His view aligns with Immunome's mission to tackle complex cancer therapies and improve patient outcomes.
Prior Roles and Achievements
Before joining Immunome, Mr. Shahar led successful projects at Seagen and maintained significant responsibilities at Eli Lilly, particularly overseeing major brands in oncology. His comprehensive understanding of the market dynamics positions Immunome to leverage his experience as they innovate and grow.
About Immunome, Inc.
Immunome is a clinical-stage biotechnology entity dedicated to developing groundbreaking therapies aimed at improving cancer treatment outcomes. The company's innovative pipeline includes not only AL102 but also other promising candidates, such as IM-1021, a ROR1-targeted antibody-drug conjugate (ADC), and IM-3050, which is a FAP-targeted radioligand currently being prepared for investigational new drug (IND) submissions expected in the near future.
Emphasis on Patient-Centric Approaches
The leadership team at Immunome proudly comprises individuals who have previously participated in creating advanced cancer therapies. They are confident in their strategy to push the boundaries of oncology treatments. As they move forward, the company will focus on translating complex scientific discoveries into tangible patient benefits.
Frequently Asked Questions
What is Immunome's focus in biotechnology?
Immunome focuses on developing innovative targeted therapies for cancer patients, aiming to improve treatment outcomes.
Who is Roee Shahar and what is his role?
Roee Shahar is the newly appointed Executive Vice President for Commercial at Immunome, bringing extensive experience in oncology product commercialization.
What significant projects does Immunome currently have?
Immunome is advancing a pipeline that includes AL102, IM-1021, and IM-3050, focusing on novel therapeutic approaches for cancer treatment.
How does Immunome plan to enhance its oncology portfolio?
The company aims to leverage Mr. Shahar's expertise to progress its targeted oncology agents and achieve strategic growth.
What emphasizes Immunome's commitment to patient care?
Immunome's focus on tackling debilitating cancers, along with a strong pipeline of therapies, underscores its commitment to improving patient care and outcomes.
